Wockhardt’s experimental drug, Zaynich, has shown impressive results, achieving a 100% cure rate in clinical trials for ...

Wockhardt, founded in 1967, now has six novel formulations in the pipeline, with a second drug Zaynich also expected to launch later in 2025 to tackle complex hospital infections.

Wockhardt Pharma share price: Wockhardt Pharma shares on Monday, December 16 were locked in at the 10% upper circuit at Rs 1,536.40, reaching a level not seen in the stock for nine years.

Testing new antibiotics in India, South Africa, or Brazil, where they are needed most, makes scientific sense. But it’s not ...

Get the latest Wockhardt-pharma news, photos, videos, and podcasts. Explore more for Wockhardt-pharma breaking news, opinions, special reports, and more on mint.

Shares of Wockhardt, the pharmaceutical and biotechnology major, spiked 9.5% in early trade on Friday, January 3, to hit a nine-year high of ₹1,583 apiece after the company announced regulatory ...

Wockhardt expects to launch this product ... he said. The active pharmaceutical ingredient would be produced at its Ankleshwar plant and the formulation (finished dosage form) at Daman, he said.

Learn about Wockhardt Ltd in Daman ... Explore more about over 8069 Pharmaceutical Companies in India through our constantly updated list. Medindia Constantly updates the database.

Mumbai: Wockhardt has announced that Zaynich (Zidebactam/Cefepime, WCK 5222) demonstrated over 97 percent clinical efficacy in treating seriously ill patients with infections caused ...

Wockhardt Hospitals ... and certification programs in the health and social care sector. 29 May 2024 The pharmaceuticals firm reported a net loss of Rs 177 crore for the fourth quarter ending ...